LGALS13
Galactoside-binding soluble lectin 13
Also known as: PLAC8, PP13, PP13_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UHV8
- Gene
- LGALS13
- Ensembl
- ENSG00000105198
- Chromosome
- 19
- Canonical length
- 139 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Lysophospholipases are enzymes that act on biological membranes to regulate the multifunctional lysophospholipids. The protein encoded by this gene has lysophospholipase activity. It is composed of two identical subunits which are held together by disulfide bonds. This protein has structural similarity to several members of the beta-galactoside-binding S-type lectin family. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
139 residues, UniProt reviewed canonical sequence.
>Q9UHV8|LGALS13
1 MSSLPVPYKL PVSLSVGSCV IIKGTPIHSF INDPQLQVDF YTDMDEDSDI AFRFRVHFGN
61 HVVMNRREFG IWMLEETTDY VPFEDGKQFE LCIYVHYNEY EIKVNGIRIY GFVHRIPPSF
121 VKMVQVSRDI SLTSVCVCNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LGALS13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.25
- Highest tissue expression
- 11 nTPM
Expression across tissuesHPA
Tissue
- placenta: 11 nTPM
- testis: 0.3 nTPM
- cerebellum: 0.2 nTPM
- midbrain: 0.2 nTPM
- retina: 0.2 nTPM
- hypothalamus: 0.1 nTPM
Single-cell type
- syncytiotrophoblasts: 590 nCPM
- late spermatids: 31 nCPM
- migrating cytotrophoblasts: 11 nCPM
- retinal amacrine cells: 6.9 nCPM
- early spermatids: 6 nCPM
- cytotrophoblasts: 3.9 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hypothalamus: 1.5 nTPM
- cerebellum: 1.2 nTPM
- midbrain: 0.9 nTPM
- pons: 0.8 nTPM
- thalamus: 0.8 nTPM
- medulla oblongata: 0.6 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.54
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.21
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- negative regulation of protein localization to plasma membrane
- phospholipid metabolic process
- positive regulation of ferroptosis
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LGALS13 as an antibody target. Whether an autoantibody or antibody against LGALS13 could matter depends on whether native LGALS13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LGALS13 is annotated as secreted, so native LGALS13 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label LGALS13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...